JAMA : the journal of the American Medical Association
-
Randomized Controlled Trial Multicenter Study
Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.
Agitation is common, persistent, and associated with adverse consequences for patients with Alzheimer disease. Pharmacological treatment options, including antipsychotics are not satisfactory. ⋯ Among patients with probable Alzheimer disease and agitation who were receiving psychosocial intervention, the addition of citalopram compared with placebo significantly reduced agitation and caregiver distress; however, cognitive and cardiac adverse effects of citalopram may limit its practical application at the dosage of 30 mg per day.
-
Randomized Controlled Trial Multicenter Study Comparative Study
Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial.
Atrial fibrillation (AF) is the most common rhythm disorder seen in clinical practice. Antiarrhythmic drugs are effective for reduction of recurrence in patients with symptomatic paroxysmal AF. Radiofrequency ablation is an accepted therapy in patients for whom antiarrhythmic drugs have failed; however, its role as a first-line therapy needs further investigation. ⋯ Among patients with paroxysmal AF without previous antiarrhythmic drug treatment, radiofrequency ablation compared with antiarrhythmic drugs resulted in a lower rate of recurrent atrial tachyarrhythmias at 2 years. However, recurrence was frequent in both groups.
-
What treatments for lower extremity superficial thrombophlebitis are associated with lower rates of venous thromboembolic events (VTE), major bleeding, and superficial venous thrombosis extension? ⋯ Fondaparinux (2.5 mg) subcutaneously once daily for 45 days is associated with fewer symptomatic VTEs and lower rates of superficial venous thrombosis extension and recurrence with no increases in major bleeding compared with placebo. Low-molecular-weight heparin and nonsteroidal anti-inflammatory drugs are associated with lower rates of superficial thrombophlebitis extension or recurrence, but data regarding symptomatic VTEs are inconclusive.